Scientists found cancer-lowering sensitivity to radiopharmacy mutations

US, WASHINGTON (ORDO NEWS) — Scientists at the University of Heidelberg (Germany) discovered DNA mutations that lower the sensitivity of prostate cancer to radiopharmaceutical therapy. Researchers described their discovery in an article in The Journal of Nuclear Medicine.

Radiopharmaceutical therapy (PSMA-TAT) is a promising new approach to treating prostate cancer, but 37% of patients respond poorly to this treatment. Preclinical and other early studies show that certain gene mutations associated with DNA damage can either increase or decrease the radiosensitivity of cancer and affect the tumor’s response to PSMA-TAT.

The authors of the study decided to find out the factors associated with this phenomenon. For this, they selected 60 patients who received such therapy. As a result, 10 patients with a poor response to PSMA-TAT were identified.

The authors took biopsies from seven out of 10 patients and found a total of 15 deletions of whole genes containing harmful and potentially harmful mutations. They were associated with the susceptibility of prostate cancer cells to radiopharmaceutical therapy.

From this, scientists concluded that a genetic study in patients with this type of cancer may allow in some cases to prescribe the most effective treatment.

“The value of our work lies in opening up the field of further research. In the long run, its results may change the approach to the diagnosis and treatment of prostate cancer, ”said the lead author of the study, chief physician of radionuclide therapy at the University of Heidelberg hospital Clemens Kratohvil.

Earlier, on May 16, scientists of the Scientific Research Institute of Traumatology and Orthopedics (NIIITO) named after Tsivya, together with colleagues from the Research Institute of Fundamental and Clinical Immunology (NIIIFKI), reported that they had developed a new method for the treatment of malignant brain tumors using a special vaccine.


Contact us: [email protected]

Our Standards, Terms of Use: Standard Terms And Conditions.